U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06841315) titled 'A Phase 1 Varegacestat Hepatic Impairment Study' on Jan. 24.
Brief Summary: This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.
Study Start Date: Feb. 25
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteer
Hepatic Impairment (HI)
Intervention:
DRUG: varegacestat
experimental intervention
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Immunome, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....